Molecular	O
basis	O
of	O
a	O
multiple	O
lymphokine	B-protein
deficiency	O
in	O
a	O
patient	O
with	O
severe	O
combined	O
immunodeficiency	O
.	O

We	O
have	O
previously	O
reported	O
that	O
the	O
T	B-cell_type
lymphocytes	I-cell_type
of	O
a	O
child	O
with	O
severe	O
combined	O
immunodeficiency	O
are	O
defective	O
in	O
the	O
transcription	O
of	O
several	O
lymphokine	B-DNA
genes	I-DNA
that	O
include	O
IL2	B-DNA
,	O
IL3	B-DNA
,	O
IL4	B-DNA
,	O
and	O
IL5	B-DNA
,	O
which	O
encode	O
interleukins	B-protein
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
(	O
IL-2	B-protein
,	O
-3	B-protein
,	O
-4	B-protein
,	O
and	O
-5	B-protein
)	O
.	O

To	O
determine	O
whether	O
the	O
defect	O
in	O
the	O
patient	O
's	O
T	B-cell_type
lymphocytes	I-cell_type
involved	O
a	O
trans-acting	B-protein
factor	I-protein
common	O
to	O
the	O
affected	O
lymphokine	B-DNA
genes	I-DNA
,	O
we	O
examined	O
the	O
ability	O
of	O
nuclear	B-protein
factors	I-protein
from	O
the	O
patient	O
's	O
T	B-cell_type
lymphocytes	I-cell_type
to	O
bind	O
response	O
elements	O
present	O
in	O
the	O
regulatory	B-DNA
region	I-DNA
of	O
IL2	B-DNA
.	O

Nuclear	B-protein
factor	I-protein
NF-kB	I-protein
,	O
activation	B-protein
protein	I-protein
1	I-protein
(	O
AP-1	B-protein
)	O
,	O
OCT-1	B-protein
,	O
and	O
NF-IL-2B	B-protein
binding	O
activity	O
were	O
normal	O
.	O

In	O
contrast	O
,	O
the	O
binding	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
to	O
its	O
response	O
element	O
in	O
the	O
IL2	B-DNA
enhancer	I-DNA
and	O
to	O
an	O
NF-AT-like	B-DNA
response	I-DNA
element	I-DNA
present	O
in	O
the	O
IL4	B-DNA
enhancer	I-DNA
was	O
abnormal	O
.	O

To	O
ascertain	O
whether	O
the	O
abnormal	O
NF-AT	B-protein
binding	O
activity	O
was	O
related	O
to	O
an	O
impaired	O
function	O
,	O
we	O
transfected	O
patient	O
and	O
control	O
T	B-cell_type
lymphocytes	I-cell_type
with	O
constructs	O
containing	O
the	O
reporter	O
gene	O
encoding	O
chloramphenicol	B-protein
acetyl	I-protein
transferase	I-protein
(	O
CAT	B-protein
)	O
under	O
the	O
control	O
of	O
the	O
entire	O
IL2	B-DNA
regulatory	I-DNA
region	I-DNA
or	O
of	O
multimers	O
of	O
individual	O
enhancer	B-DNA
sequences	I-DNA
.	O

CAT	O
expression	O
directed	O
by	O
the	O
IL2	B-DNA
regulatory	I-DNA
region	I-DNA
or	O
by	O
a	O
multimer	O
of	O
the	O
NF-AT-binding	B-DNA
site	I-DNA
was	O
markedly	O
lower	O
in	O
the	O
patient	O
relative	O
to	O
controls	O
.	O

In	O
contrast	O
,	O
CAT	B-DNA
gene	I-DNA
expression	O
directed	O
by	O
a	O
multimer	O
of	O
the	O
OCT-1	B-DNA
proximal	I-DNA
(	I-DNA
OCT-1p	I-DNA
)	I-DNA
-binding	I-DNA
site	I-DNA
was	O
equivalent	O
in	O
patient	O
and	O
controls	O
.	O

These	O
results	O
indicate	O
that	O
an	O
abnormality	O
of/or	O
influencing	O
NF-AT	B-protein
may	O
underlie	O
the	O
multiple	O
lymphokine	B-protein
deficiency	O
in	O
this	O
patient	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

90	NULL
,	NULL
pp	NULL
.	NULL

4728-4732	NULL
,	NULL
May	NULL
1993	NULL
Immunology	NULL
Molecular	NULL
basis	NULL
of	NULL
a	NULL
multiple	NULL
lymphokine	NULL
deficiency	NULL
in	NULL
a	NULL
patient	NULL
with	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
EMANUELA	NULL
CASTIGLI*	NULL
,	NULL
RAJENDRA	NULL
Panwat	NULL
,	NULL
RoseErt	NULL
A.	NULL
Goop	NULL
#	NULL
,	NULL
Rar	NULL
S.	NULL
GEna*	NULL
,	NULL
AND	NULL
TALAL	NULL
A.	NULL
CHATILA*	NULL
*Division	NULL
of	NULL
Allergy	NULL
and	NULL
Immunology	NULL
,	NULL
Children	NULL
's	NULL
Hospital	NULL
,	NULL
and	NULL
Department	NULL
of	NULL
Pediatrics	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
;	NULL
'Department	NULL
of	NULL
Pediatrics	NULL
,	NULL
North	NULL
Shore	NULL
University	NULL
Hospital	NULL
,	NULL
Manhasset	NULL
,	NULL
NY	NULL
11030	NULL
;	NULL
and	NULL
*Department	NULL
of	NULL
Pediatrics	NULL
,	NULL
All	NULL
Children	NULL
's	NULL
Hospital	NULL
,	NULL
University	NULL
of	NULL
South	NULL
Florida	NULL
,	NULL
St.	NULL
Petersburg	NULL
,	NULL
FL	NULL
33701	NULL
Contributed	NULL
by	NULL
Robert	NULL
A	NULL
.	NULL

Good	NULL
,	NULL
January	NULL
21	NULL
,	NULL
1993	NULL
ABSTRACT	NULL
We	NULL
have	NULL
previously	NULL
reported	NULL
that	NULL
the	NULL
T	NULL
lymphocytes	NULL
of	NULL
a	NULL
child	NULL
with	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
are	NULL
defective	NULL
in	NULL
the	NULL
transcription	NULL
of	NULL
several	NULL
lymphokine	NULL
genes	NULL
that	NULL
include	NULL
IL2	NULL
,	NULL
IL	NULL
3	NULL
,	NULL
IL4	NULL
,	NULL
and	NULL
ILS	NULL
,	NULL
which	NULL
encode	NULL
interleukins	NULL
2	NULL
,	NULL
3	NULL
,	NULL
4	NULL
,	NULL
and	NULL
5	NULL
(	NULL
IL-2	NULL
,	NULL
-3	NULL
,	NULL
-4	NULL
,	NULL
and	NULL
-	NULL
5	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
defect	NULL
in	NULL
the	NULL
patient	NULL
's	NULL
T	NULL
lymphocytes	NULL
involved	NULL
a	NULL
trans-acting	NULL
factor	NULL
common	NULL
to	NULL
the	NULL
affected	NULL
lymphokine	NULL
genes	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
nuclear	NULL
factors	NULL
from	NULL
the	NULL
patient	NULL
's	NULL
T	NULL
lymphocytes	NULL
to	NULL
bind	NULL
response	NULL
elements	NULL
present	NULL
in	NULL
the	NULL
regulatory	NULL
region	NULL
of	NULL
ZL2	NULL
.	NULL

Nuclear	NULL
factor	NULL
NF-kB	NULL
,	NULL
activation	NULL
protein	NULL
1	NULL
(	NULL
AP-1	NULL
)	NULL
,	NULL
OCT-1	NULL
,	NULL
and	NULL
NF-IL-2B	NULL
binding	NULL
activity	NULL
were	NULL
normal	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NF-AT	NULL
)	NULL
to	NULL
its	NULL
response	NULL
element	NULL
in	NULL
the	NULL
ZL2	NULL
enhancer	NULL
and	NULL
to	NULL
an	NULL
NF-AT-like	NULL
response	NULL
element	NULL
present	NULL
in	NULL
the	NULL
ZL4	NULL
enhancer	NULL
was	NULL
abnormal	NULL
.	NULL

To	NULL
ascertain	NULL
whether	NULL
the	NULL
abnormal	NULL
NF-AT	NULL
binding	NULL
activity	NULL
was	NULL
related	NULL
to	NULL
an	NULL
impaired	NULL
function	NULL
,	NULL
we	NULL
transfected	NULL
patient	NULL
and	NULL
control	NULL
T	NULL
lymphocytes	NULL
with	NULL
constructs	NULL
containing	NULL
the	NULL
reporter	NULL
gene	NULL
encoding	NULL
chloramphenicol	NULL
acetyl	NULL
transferase	NULL
(	NULL
CAT	NULL
)	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
entire	NULL
ZL2	NULL
regulatory	NULL
region	NULL
or	NULL
of	NULL
multimers	NULL
of	NULL
individual	NULL
enhancer	NULL
sequences	NULL
.	NULL

CAT	NULL
expression	NULL
directed	NULL
by	NULL
the	NULL
ZL2	NULL
regulatory	NULL
region	NULL
or	NULL
by	NULL
a	NULL
multimer	NULL
of	NULL
the	NULL
NF-AT-binding	NULL
site	NULL
was	NULL
markedly	NULL
lower	NULL
in	NULL
the	NULL
patient	NULL
relative	NULL
to	NULL
controls	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
CAT	NULL
gene	NULL
expression	NULL
directed	NULL
by	NULL
a	NULL
multimer	NULL
of	NULL
the	NULL
OCT-1	NULL
proximal	NULL
(	NULL
OCT-1p	NULL
)	NULL
-binding	NULL
site	NULL
was	NULL
equivalent	NULL
in	NULL
patient	NULL
and	NULL
controls	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
an	NULL
abnormality	NULL
of	NULL
/or	NULL
influencing	NULL
NF-AT	NULL
may	NULL
underlie	NULL
the	NULL
multiple	NULL
lymphokine	NULL
deficiency	NULL
in	NULL
this	NULL
patient	NULL
.	NULL

Induction	NULL
of	NULL
lymphokine	NULL
gene	NULL
expression	NULL
is	NULL
mediated	NULL
by	NULL
trans-acting	NULL
factors	NULL
that	NULL
interact	NULL
with	NULL
specific	NULL
DNA	NULL
elements	NULL
present	NULL
in	NULL
the	NULL
regulatory	NULL
region	NULL
of	NULL
these	NULL
genes	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
gene	NULL
(	NULL
designated	NULL
ZL2	NULL
)	NULL
expression	NULL
is	NULL
one	NULL
of	NULL
the	NULL
best	NULL
characterized	NULL
among	NULL
the	NULL
T	NULL
cell-specific	NULL
lymphokine	NULL
genes	NULL
.	NULL

IL2	NULL
transcription	NULL
requires	NULL
the	NULL
binding	NULL
of	NULL
common	NULL
regulatory	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
OCT-1	NULL
,	NULL
activation	NULL
protein	NULL
1	NULL
(	NULL
AP-1	NULL
)	NULL
,	NULL
and	NULL
nuclear	NULL
factor	NULL
NF-kB	NULL
,	NULL
which	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
several	NULL
genes	NULL
in	NULL
lymphoid	NULL
as	NULL
well	NULL
as	NULL
nonlymphoid	NULL
cells	NULL
(	NULL
reviewed	NULL
in	NULL
ref	NULL
.	NULL

1	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
IL2	NULL
expression	NULL
requires	NULL
specific	NULL
regulatory	NULL
factors	NULL
like	NULL
NF-AT	NULL
,	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
NF-AT	NULL
,	NULL
like	NULL
the	NULL
expression	NULL
of	NULL
IZL2	NULL
,	NULL
is	NULL
T	NULL
cell-restricted	NULL
(	NULL
2	NULL
)	NULL
and	NULL
tightly	NULL
linked	NULL
to	NULL
T-cell	NULL
activation	NULL
(	NULL
3	NULL
,	NULL
8-10	NULL
)	NULL
.	NULL

In	NULL
a	NULL
previous	NULL
report	NULL
we	NULL
described	NULL
a	NULL
child	NULL
with	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
with	NULL
a	NULL
normal	NULL
number	NULL
of	NULL
circulating	NULL
T	NULL
cells	NULL
and	NULL
poor	NULL
T-lymphocyte	NULL
proliferation	NULL
to	NULL
mitogens	NULL
,	NULL
which	NULL
was	NULL
corrected	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
by	NULL
recombinant	NULL
IL-2	NULL
(	NULL
rIL-2	NULL
)	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Further	NULL
studies	NULL
showed	NULL
that	NULL
the	NULL
patient	NULL
's	NULL
T	NULL
lymphocytes	NULL
were	NULL
defective	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
and	NULL
IL-5	NULL
mRNAs	NULL
as	NULL
a	NULL
result	NULL
of	NULL
decreased	NULL
transcription	NULL
of	NULL
IL2	NULL
,	NULL
IL	NULL
3	NULL
,	NULL
IL4	NULL
,	NULL
and	NULL
ILS	NULL
.	NULL

The	NULL
expression	NULL
by	NULL
T	NULL
lymphocytes	NULL
of	NULL
other	NULL
cytokines	NULL
such	NULL
as	NULL
granulocyte/	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

$	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

4728	NULL
zee	NULL
|-	NULL
``	NULL
200	NULL
+108	NULL
Transcription	NULL
NF-AT	NULL
NF-kB	NULL
start	NULL
site	NULL
~18¢	NULL
~184	NULL
-	NULL
=	NULL
CD28RC	NULL
OoCt-1	NULL
+oap	NULL
49	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Transacting	NULL
factors	NULL
binding	NULL
their	NULL
response	NULL
elements	NULL
in	NULL
the	NULL
enhancer	NULL
of	NULL
The	NULL
numbers	NULL
represent	NULL
the	NULL
5	NULL
'	NULL
position	NULL
relative	NULL
to	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
(	NULL
0	NULL
)	NULL
.	NULL

Nuclear	NULL
factors	NULL
are	NULL
NF-AT	NULL
,	NULL
OCT-1	NULL
,	NULL
NF-kB	NULL
,	NULL
AP-1	NULL
,	NULL
NF-IL-2B	NULL
(	NULL
1-4	NULL
)	NULL
,	NULL
and	NULL
OCT-1	NULL
+	NULL
OCT-1	NULL
associated	NULL
protein	NULL
(	NULL
OAP	NULL
)	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Recently	NULL
two	NULL
more	NULL
trans-acting	NULL
factors	NULL
involved	NULL
in	NULL
IL2	NULL
regulation	NULL
have	NULL
been	NULL
described	NULL
.	NULL

CD28	NULL
stimulation	NULL
induces	NULL
expression	NULL
of	NULL
a	NULL
CD28	NULL
response	NULL
complex	NULL
(	NULL
CD28RC	NULL
)	NULL
,	NULL
which	NULL
possesses	NULL
enhancer	NULL
activity	NULL
(	NULL
6	NULL
)	NULL
.	NULL

The	NULL
second	NULL
one	NULL
suppresses	NULL
expression	NULL
and	NULL
binds	NULL
a	NULL
sequence	NULL
called	NULL
'negative	NULL
response	NULL
element	NULL
A	NULL
``	NULL
``	NULL
(	NULL
NRE-A	NULL
)	NULL
(	NULL
7	NULL
)	NULL
.	NULL

macrophage	NULL
colony-stimulating	NULL
factor	NULL
and	NULL
interleukin	NULL
6	NULL
,	NULL
both	NULL
of	NULL
which	NULL
are	NULL
not	NULL
T	NULL
lymphocyte-restricted	NULL
,	NULL
was	NULL
not	NULL
affected	NULL
(	NULL
12	NULL
)	NULL
.	NULL

A	NULL
defect	NULL
in	NULL
a	NULL
T	NULL
lymphocyte-specific	NULL
trans-acting	NULL
protein	NULL
required	NULL
for	NULL
the	NULL
transcription	NULL
of	NULL
IL2	NULL
and	NULL
other	NULL
T	NULL
cell-restricted	NULL
lymphokine	NULL
genes	NULL
could	NULL
account	NULL
for	NULL
impaired	NULL
lymphokine	NULL
expression	NULL
.	NULL

To	NULL
address	NULL
the	NULL
question	NULL
of	NULL
whether	NULL
a	NULL
regulatory	NULL
factor	NULL
could	NULL
be	NULL
defective	NULL
in	NULL
the	NULL
patient	NULL
's	NULL
T	NULL
lymphocytes	NULL
,	NULL
we	NULL
used	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSA	NULL
)	NULL
to	NULL
examine	NULL
the	NULL
binding	NULL
activities	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
patient	NULL
T	NULL
lymphocytes	NULL
and	NULL
specific	NULL
for	NULL
response	NULL
elements	NULL
(	NULL
binding	NULL
sites	NULL
)	NULL
present	NULL
in	NULL
the	NULL
ZL2	NULL
and	NULL
IL4	NULL
enhancer	NULL
.	NULL

We	NULL
also	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
trans-acting	NULL
factors	NULL
/response	NULL
elements	NULL
to	NULL
direct	NULL
the	NULL
transcription	NULL
of	NULL
a	NULL
reporter	NULL
gene	NULL
,	NULL
chloramphenicol	NULL
acetyl-transferase	NULL
(	NULL
CAT	NULL
)	NULL
,	NULL
in	NULL
patient	NULL
and	NULL
control	NULL
T	NULL
lymphocytes	NULL
.	NULL

We	NULL
demonstrate	NULL
here	NULL
that	NULL
the	NULL
patient	NULL
's	NULL
T	NULL
lymphocytes	NULL
have	NULL
an	NULL
abnormality	NULL
in	NULL
the	NULL
binding	NULL
activity	NULL
of	NULL
NF-AT	NULL
.	NULL

This	NULL
abnormality	NULL
was	NULL
determined	NULL
to	NULL
be	NULL
functionally	NULL
important	NULL
because	NULL
it	NULL
is	NULL
accompanied	NULL
by	NULL
defective	NULL
NF-AT-enhancer	NULL
activity	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
T-Cell	NULL
Lines	NULL
.	NULL

T-cell	NULL
lines	NULL
were	NULL
prepared	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
of	NULL
the	NULL
patient	NULL
or	NULL
healthy	NULL
volunteers	NULL
by	NULL
stimulation	NULL
with	NULL
phytohemagglutinin	NULL
P	NULL
(	NULL
Difco	NULL
)	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Nuclear	NULL
Extracts	NULL
.	NULL

T	NULL
lymphocytes	NULL
were	NULL
incubated	NULL
with	NULL
medium	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
20	NULL
ng	NULL
of	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
(	NULL
Sigma	NULL
)	NULL
per	NULL
ml	NULL
and	NULL
0.5	NULL
uM	NULL
ionomycin	NULL
(	NULL
Calbiochem	NULL
)	NULL
for	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
8	NULL
hr	NULL
.	NULL

Nuclear	NULL
extracts	NULL
Abbreviations	NULL
:	NULL
IL-2	NULL
,	NULL
-3	NULL
,	NULL
-4	NULL
,	NULL
and	NULL
-5	NULL
,	NULL
interleukins	NULL
2	NULL
,	NULL
3	NULL
,	NULL
4	NULL
,	NULL
and	NULL
5	NULL
;	NULL
rIL-2	NULL
,	NULL
recombinant	NULL
IL-2	NULL
;	NULL
NF-AT	NULL
,	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
;	NULL
AP-1	NULL
,	NULL
ac-gvation	NULL
protein	NULL
1	NULL
;	NULL
OCT-1p	NULL
,	NULL
OCT-1	NULL
proximal	NULL
;	NULL
TCGF	NULL
,	NULL
T-cell	NULL
growth	NULL
actor	NULL
.	NULL

Immunology	NULL
:	NULL
Castigli	NULL
et	NULL
al	NULL
.	NULL

were	NULL
prepared	NULL
as	NULL
described	NULL
by	NULL
Ohisson	NULL
et	NULL
al	NULL
.	NULL

(	NULL
13	NULL
)	NULL
,	NULL
with	NULL
minor	NULL
modifications	NULL
in	NULL
the	NULL
composition	NULL
of	NULL
buffers	NULL
A	NULL
and	NULL
C	NULL
and	NULL
in	NULL
the	NULL
procedure	NULL
for	NULL
preparation	NULL
of	NULL
the	NULL
nuclei	NULL
.	NULL

Briefly	NULL
5-10	NULL
x	NULL
10®	NULL
T	NULL
lymphocytes	NULL
were	NULL
washed	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
,	NULL
resuspended	NULL
in	NULL
buffer	NULL
A	NULL
containing	NULL
2	NULL
ug	NULL
of	NULL
protease	NULL
inhibitors	NULL
(	NULL
leupeptin	NULL
,	NULL
antipain	NULL
,	NULL
and	NULL
pepstatin	NULL
;	NULL
Sigma	NULL
)	NULL
per	NULL
ml	NULL
and	NULL
0.03	NULL
%	NULL
Nonidet	NULL
P-40	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
and	NULL
kept	NULL
on	NULL
ice	NULL
for	NULL
5	NULL
min	NULL
.	NULL

Nuclei	NULL
were	NULL
then	NULL
pelleted	NULL
at	NULL
200	NULL
x	NULL
g	NULL
and	NULL
resuspended	NULL
in	NULL
buffer	NULL
C	NULL
containing	NULL
2	NULL
ug	NULL
of	NULL
protease	NULL
inhibitors	NULL
per	NULL
ml	NULL
.	NULL

All	NULL
other	NULL
steps	NULL
were	NULL
performed	NULL
exactly	NULL
as	NULL
described	NULL
in	NULL
ref	NULL
.	NULL

9	NULL
.	NULL

Oligonucleotides	NULL
.	NULL

Double-stranded	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
NF-AT-binding	NULL
site	NULL
or	NULL
NF-IL-2B	NULL
site	NULL
from	NULL
the	NULL
ZL2	NULL
enhancer	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
(	NULL
2	NULL
)	NULL
,	NULL
the	NULL
NF-AT-like	NULL
site	NULL
from	NULL
the	NULL
IL4	NULL
enhancer	NULL
(	NULL
14	NULL
)	NULL
,	NULL
and	NULL
a	NULL
mutant	NULL
NF-AT	NULL
response	NULL
element	NULL
were	NULL
gifts	NULL
of	NULL
G.	NULL
R.	NULL
Crabtree	NULL
(	NULL
Stanford	NULL
University	NULL
School	NULL
of	NULL
Med-icine	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
Oct-1	NULL
proximal	NULL
(	NULL
OCT-1p	NULL
)	NULL
site	NULL
(	NULL
of	NULL
the	NULL
IL2	NULL
enhancer	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
(	NULL
2	NULL
)	NULL
and	NULL
the	NULL
AP-1	NULL
site	NULL
,	NULL
derived	NULL
from	NULL
the	NULL
human	NULL
metallothionein	NULL
II	NULL
,	NULL
gene	NULL
promoter	NULL
(	NULL
15	NULL
)	NULL
,	NULL
were	NULL
synthesized	NULL
on	NULL
an	NULL
Applied	NULL
Biosystems	NULL
DNA	NULL
synthesizer	NULL
391	NULL
.	NULL

The	NULL
NF-kB	NULL
site	NULL
,	NULL
derived	NULL
from	NULL
the	NULL
k	NULL
light	NULL
chain	NULL
gene	NULL
enhancer	NULL
(	NULL
16	NULL
)	NULL
,	NULL
was	NULL
purchased	NULL
from	NULL
GIBCO/BRL	NULL
.	NULL

EMSA	NULL
.	NULL

Double-stranded	NULL
oligonucleotides	NULL
were	NULL
end-labeled	NULL
with	NULL
the	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
)	NULL
/	NULL
[	NULL
y	NULL
``	NULL
2P	NULL
]	NULL
ATP	NULL
(	NULL
New	NULL
England	NULL
Nuclear	NULL
)	NULL
method	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
16-20	NULL
ul	NULL
(	NULL
final	NULL
volume	NULL
)	NULL
of	NULL
binding	NULL
buffer	NULL
(	NULL
17	NULL
)	NULL
containing	NULL
2.5-5	NULL
ug	NULL
of	NULL
nuclear	NULL
proteins	NULL
,	NULL
2-4	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Pharmacia	NULL
LKB	NULL
)	NULL
,	NULL
and	NULL
0.05-0.1	NULL
ng	NULL
of	NULL
*P-end-labeled	NULL
double-stranded	NULL
oligonucleotide	NULL
.	NULL

For	NULL
competition	NULL
experiments	NULL
,	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
double-stranded	NULL
oligonucleotides	NULL
were	NULL
added	NULL
together	NULL
with	NULL
the	NULL
labeled	NULL
ones	NULL
.	NULL

The	NULL
binding	NULL
mixtures	NULL
were	NULL
incubated	NULL
for	NULL
60	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
when	NULL
NF-AT	NULL
and	NULL
NF-IL-2B	NULL
were	NULL
tested	NULL
and	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
when	NULL
OCT-1p	NULL
,	NULL
NF-kB	NULL
,	NULL
or	NULL
AP-1	NULL
were	NULL
analyzed	NULL
.	NULL

DNA-protein	NULL
complexes	NULL
were	NULL
then	NULL
resolved	NULL
on	NULL
a	NULL
5	NULL
%	NULL
poly-acrylamide	NULL
gel	NULL
in	NULL
0.5	NULL
x	NULL
TBE	NULL
(	NULL
90	NULL
mM	NULL
Tris/90	NULL
mM	NULL
boric	NULL
acid/2	NULL
mM	NULL
EDTA	NULL
,	NULL
pH	NULL
8	NULL
)	NULL
at	NULL
4°C	NULL
followed	NULL
by	NULL
autoradiography	NULL
.	NULL

Plasmid	NULL
Constructs	NULL
.	NULL

p-IL-2154CX	NULL
,	NULL
p22-6AXho	NULL
,	NULL
and	NULL
pg42CAT	NULL
constructs	NULL
respectively	NULL
contained	NULL
the	NULL
-319	NULL
to	NULL
+52	NULL
sequence	NULL
of	NULL
JL2	NULL
,	NULL
the	NULL
minimal	NULL
ZL2	NULL
promoter	NULL
spanning	NULL
-70	NULL
to	NULL
+52	NULL
,	NULL
and	NULL
the	NULL
y-fibrinogen	NULL
promoter	NULL
,	NULL
placed	NULL
upstream	NULL
from	NULL
the	NULL
CAT	NULL
gene	NULL
.	NULL

NF-AT-CAT	NULL
(	NULL
®3	NULL
)	NULL
and	NULL
OCT-lp	NULL
CAT	NULL
(	NULL
x4	NULL
)	NULL
constructs	NULL
contained	NULL
three	NULL
and	NULL
four	NULL
copies	NULL
,	NULL
respectively	NULL
,	NULL
of	NULL
the	NULL
NF-AT	NULL
or	NULL
OCT-1p	NULL
sites	NULL
from	NULL
the	NULL
enhancer	NULL
of	NULL
ZL2	NULL
,	NULL
all	NULL
of	NULL
them	NULL
placed	NULL
upstream	NULL
of	NULL
the	NULL
y-fibrinogen	NULL
promoter	NULL
(	NULL
2	NULL
)	NULL
.	NULL

All	NULL
of	NULL
these	NULL
plasmids	NULL
were	NULL
provided	NULL
by	NULL
Gerald	NULL
R.	NULL
Crabtree	NULL
.	NULL

AP-1-containing	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
AP-1	NULL
site	NULL
from	NULL
the	NULL
human	NULL
metallothionein	NULL
IIa	NULL
,	NULL
gene	NULL
promoter	NULL
(	NULL
15	NULL
)	NULL
,	NULL
and	NULL
NF-kB-CAT	NULL
(	NULL
X4	NULL
)	NULL
,	NULL
containing	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
sequence	NULL
for	NULL
the	NULL
NF-kB	NULL
site	NULL
from	NULL
the	NULL
k	NULL
light	NULL
chain	NULL
enhancer	NULL
(	NULL
16	NULL
)	NULL
,	NULL
were	NULL
constructed	NULL
by	NULL
ligating	NULL
multimerized	NULL
AP-1	NULL
and	NULL
NF-kB	NULL
oligonucleotides	NULL
to	NULL
the	NULL
CAT-promoter	NULL
plasmid	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

The	NULL
plasmids	NULL
were	NULL
purified	NULL
by	NULL
equilibrium	NULL
centrifugation	NULL
in	NULL
CsCl/	NULL
ethidium	NULL
bromide	NULL
gradient	NULL
and	NULL
were	NULL
sequenced	NULL
by	NULL
standard	NULL
procedures	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Transfection	NULL
and	NULL
CAT	NULL
Assay	NULL
.	NULL

DEAE-dextran-mediated	NULL
transfection	NULL
procedure	NULL
was	NULL
used	NULL
to	NULL
introduce	NULL
plasmid	NULL
DNA	NULL
in	NULL
the	NULL
T	NULL
lymphocytes	NULL
.	NULL

Patient	NULL
and	NULL
control	NULL
T-cell	NULL
lines	NULL
were	NULL
stimulated	NULL
with	NULL
phytohemagglutinin	NULL
P	NULL
at	NULL
10	NULL
ug/ml	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
irradiated	NULL
allogeneic	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
,	NULL
partially	NULL
purified	NULL
T-cell	NULL
growth	NULL
factor	NULL
(	NULL
TCGF	NULL
)	NULL
(	NULL
12	NULL
)	NULL
,	NULL
and	NULL
10	NULL
units	NULL
of	NULL
rIL-2	NULL
per	NULL
ml	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
harvested	NULL
4-5	NULL
days	NULL
later	NULL
,	NULL
centrifuged	NULL
over	NULL
Ficoll	NULL
,	NULL
washed	NULL
,	NULL
resuspended	NULL
at	NULL
20	NULL
x	NULL
10°	NULL
cells	NULL
per	NULL
ml	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
a	NULL
buffer	NULL
(	NULL
137	NULL
mM	NULL
NaCI/§5	NULL
mM	NULL
KCI/O0.4	NULL
mM	NULL
Na	NULL
;	NULL
HPO	NULL
,	NULL
/25	NULL
mM	NULL
TrisHCl/0.1	NULL
mg	NULL
of	NULL
MgC	NULL
]	NULL
;	NULL
per	NULL
ml/O0.1	NULL
mg	NULL
of	NULL
CaCl	NULL
;	NULL
per	NULL
mi	NULL
,	NULL
pH	NULL
7.4	NULL
)	NULL
containing	NULL
20	NULL
ug	NULL
of	NULL
plasmid	NULL
DNA	NULL
and	NULL
0.25	NULL
mg	NULL
of	NULL
DEAE-dextran	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
and	NULL
incubated	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
resuspended	NULL
in	NULL
10	NULL
mt	NULL
of	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
of	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
and	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

Thereafter	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
pelleted	NULL
,	NULL
resuspended	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
(	NULL
1993	NULL
)	NULL
4729	NULL
in	NULL
20	NULL
mi	NULL
of	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
,	NULL
2.5	NULL
%	NULL
TCGF	NULL
,	NULL
and	NULL
rIL-2	NULL
at	NULL
10	NULL
units/ml	NULL
,	NULL
and	NULL
equally	NULL
divided	NULL
in	NULL
two	NULL
flasks	NULL
.	NULL

Approximately	NULL
40	NULL
hr	NULL
after	NULL
transfection	NULL
,	NULL
one	NULL
of	NULL
the	NULL
aliquots	NULL
was	NULL
stimulated	NULL
with	NULL
20	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
and	NULL
0.5	NULL
uM	NULL
ionomycin	NULL
.	NULL

Eight	NULL
hours	NULL
later	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
spun	NULL
down	NULL
,	NULL
washed	NULL
with	NULL
PBS	NULL
at	NULL
4°C	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
150	NULL
ul	NULL
of	NULL
0.25	NULL
M	NULL
TrisHCl	NULL
(	NULL
pH	NULL
8	NULL
)	NULL
.	NULL

Cell	NULL
extracts	NULL
and	NULL
the	NULL
CAT	NULL
assay	NULL
were	NULL
performed	NULL
by	NULL
following	NULL
the	NULL
Promega	NULL
Protocol	NULL
and	NULL
Applications	NULL
Guide	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
equalized	NULL
for	NULL
the	NULL
protein	NULL
content	NULL
(	NULL
cpm/ug	NULL
)	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
the	NULL
T	NULL
lymphocytes	NULL
were	NULL
cotransfected	NULL
with	NULL
pCMV-human	NULL
growth	NULL
hormone	NULL
(	NULL
hGH	NULL
)	NULL
internal	NULL
control	NULL
plasmid	NULL
(	NULL
pCMV-GH	NULL
)	NULL
(	NULL
18	NULL
)	NULL
to	NULL
evaluate	NULL
the	NULL
transfection	NULL
efficiency	NULL
.	NULL

The	NULL
hGH	NULL
values	NULL
were	NULL
used	NULL
to	NULL
normalize	NULL
the	NULL
CAT	NULL
specific	NULL
activity	NULL
.	NULL

Protein	NULL
Assay	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
determined	NULL
with	NULL
bicinchoninic	NULL
acid	NULL
(	NULL
BCA	NULL
)	NULL
protein	NULL
assay	NULL
reagent	NULL
(	NULL
Pierce	NULL
)	NULL
.	NULL

RESULTS	NULL
We	NULL
used	NULL
EMSA	NULL
to	NULL
analyze	NULL
the	NULL
specific	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
from	NULL
patient	NULL
and	NULL
control	NULL
T	NULL
lymphocytes	NULL
to	NULL
functionally	NULL
important	NULL
sequences	NULL
present	NULL
in	NULL
the	NULL
ZL2	NULL
enhancer	NULL
.	NULL

EMSA	NULL
performed	NULL
with	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
OCT-lp-binding	NULL
site	NULL
of	NULL
the	NULL
IL2	NULL
enhancer	NULL
(	NULL
2	NULL
)	NULL
revealed	NULL
a	NULL
specific	NULL
retarded	NULL
band	NULL
when	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
control	NULL
T	NULL
lymphocytes	NULL
either	NULL
unstimulated	NULL
or	NULL
stimulated	NULL
for	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
8	NULL
hr	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
lanes	NULL
6-10	NULL
)	NULL
.	NULL

The	NULL
same	NULL
shift	NULL
pattern	NULL
was	NULL
obtained	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
patient	NULL
T	NULL
lymphocytes	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
lanes	NULL
2-5	NULL
)	NULL
.	NULL

When	NULL
nuclear	NULL
extracts	NULL
from	NULL
stimulated	NULL
T	NULL
lymphocytes	NULL
were	NULL
used	NULL
for	NULL
the	NULL
binding	NULL
to	NULL
oligonucleotides	NULL
containing	NULL
AP-1-	NULL
,	NULL
NF-kB-	NULL
,	NULL
or	NULL
NF-IL2B-binding	NULL
sites	NULL
,	NULL
we	NULL
detected	NULL
similar	NULL
migration	NULL
patterns	NULL
in	NULL
both	NULL
patient	NULL
and	NULL
control	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lanes	NULL
3-6	NULL
and	NULL
8-13	NULL
;	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lanes	NULL
3-5	NULL
and	NULL
7-10	NULL
;	NULL
and	NULL
Fig	NULL
.	NULL

2D	NULL
,	NULL
lanes	NULL
3-7	NULL
and	NULL
9-13	NULL
)	NULL
.	NULL

This	NULL
binding	NULL
activity	NULL
was	NULL
either	NULL
not	NULL
present	NULL
or	NULL
weakly	NULL
expressed	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
unstimulated	NULL
patient	NULL
and	NULL
control	NULL
T	NULL
lymphocytes	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
7	NULL
;	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
;	NULL
and	NULL
Fig	NULL
.	NULL

2D	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
8	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
using	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
NF-AT	NULL
response	NULL
element	NULL
,	NULL
we	NULL
detected	NULL
an	NULL
abnormality	NULL
in	NULL
the	NULL
shift	NULL
pattern	NULL
obtained	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
patient	NULL
T	NULL
lymphocytes	NULL
.	NULL

Fig	NULL
.	NULL

3A	NULL
shows	NULL
that	NULL
stimulation	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
for	NULL
2	NULL
hr	NULL
induced	NULL
an	NULL
NF-AT	NULL
binding	NULL
activity	NULL
in	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
patient	NULL
T	NULL
lymphocytes	NULL
that	NULL
was	NULL
comparable	NULL
to	NULL
the	NULL
control	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
compare	NULL
lane	NULL
3	NULL
with	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

However	NULL
at	NULL
4	NULL
and	NULL
8	NULL
hr	NULL
poststimulation	NULL
,	NULL
the	NULL
patient	NULL
DNA-NF-AT	NULL
complex	NULL
exhibited	NULL
faster	NULL
mobility	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
control	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
compare	NULL
lanes	NULL
10	NULL
and	NULL
11	NULL
with	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

To	NULL
evaluate	NULL
whether	NULL
such	NULL
abnormal	NULL
binding	NULL
activity	NULL
was	NULL
common	NULL
to	NULL
NF-AT-like	NULL
elements	NULL
present	NULL
in	NULL
the	NULL
enhancer	NULL
of	NULL
other	NULL
lymphokine	NULL
genes	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
ability	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
activated	NULL
patient	NULL
and	NULL
control	NULL
T	NULL
lymphocytes	NULL
to	NULL
bind	NULL
to	NULL
an	NULL
NF-AT-like	NULL
sequence	NULL
present	NULL
in	NULL
the	NULL
enhancer	NULL
of	NULL
IL4	NULL
.	NULL

This	NULL
sequence	NULL
,	NULL
which	NULL
spans	NULL
between	NULL
-122	NULL
and	NULL
-150	NULL
upstream	NULL
from	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
(	NULL
14	NULL
)	NULL
,	NULL
has	NULL
68	NULL
%	NULL
homology	NULL
with	NULL
the	NULL
NF-AT	NULL
sequence	NULL
in	NULL
the	NULL
IL2	NULL
enhancer	NULL
.	NULL

Cross-competition	NULL
experiments	NULL
with	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
IL2	NULL
or	NULL
the	NULL
IL4	NULL
NF-AT-like	NULL
response	NULL
element	NULL
demonstrated	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
IL4	NULL
sequence	NULL
for	NULL
NF-AT	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
EMSA	NULL
performed	NULL
with	NULL
this	NULL
sequence	NULL
and	NULL
nuclear	NULL
extract	NULL
from	NULL
the	NULL
patient	NULL
T	NULL
lymphocytes	NULL
showed	NULL
an	NULL
abnormal	NULL
shift	NULL
pattern	NULL
similar	NULL
to	NULL
that	NULL
obtained	NULL
with	NULL
the	NULL
NF-AT	NULL
response	NULL
element	NULL
of	NULL
the	NULL
ZL2	NULL
enhancer	NULL
(	NULL
compare	NULL
lanes	NULL
10	NULL
and	NULL
11	NULL
of	NULL
Fig	NULL
.	NULL

3A	NULL
with	NULL
lanes	NULL
10	NULL
and	NULL
11	NULL
of	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

The	NULL
protein	NULL
subunits	NULL
of	NULL
NF-AT	NULL
have	NULL
not	NULL
been	NULL
fully	NULL
char-acterized	NULL
.	NULL

However	NULL
NF-AT	NULL
has	NULL
been	NULL
recently	NULL
described	NULL
as	NULL
a	NULL
protein	NULL
complex	NULL
having	NULL
at	NULL
least	NULL
two	NULL
components	NULL
:	NULL
a	NULL
nuclear	NULL
component	NULL
that	NULL
is	NULL
inducible	NULL
upon	NULL
T-lymphocyte	NULL
activation	NULL
but	NULL
is	NULL
not	NULL
T	NULL
cell-restricted	NULL
and	NULL
a	NULL
constitutive	NULL
cytoplasmic	NULL
component	NULL
that	NULL
is	NULL
T	NULL
cell-restricted	NULL
and	NULL
that	NULL
translocates	NULL
to	NULL
the	NULL
nucleus	NULL
after	NULL
a	NULL
rise	NULL
in	NULL
intracellular	NULL
free	NULL
Ca**	NULL
concentra-	NULL
4730	NULL
Immunology	NULL
:	NULL
Castigli	NULL
et	NULL
al	NULL
.	NULL

PATIENT	NULL
CONTROL	NULL
-	NULL
TG	NULL
#	NULL
4	NULL
T2	NULL
4	NULL
B	NULL
O6	NULL
)	NULL
=-	NULL
be	NULL
-	NULL
=	NULL
&	NULL
_	NULL
competitor	NULL
Mi	NULL
ini	NULL
als	NULL
Ab	NULL
CONTROL	NULL
PATIENT	NULL
-	NULL
10	NULL
2	NULL
4	NULL
8	NULL
8	NULL
!	NULL

!	NULL

0	NULL
2	NULL
4	NULL
8	NULL
8	NULL
``	NULL
hrs	NULL
(	NULL
PMA+io	NULL
)	NULL
-o	NULL
<	NULL
_	NULL
&	NULL
0	NULL
e	NULL
&	NULL
o	NULL
&	NULL
o_	NULL
ce	NULL
o-	NULL
coe	NULL
%	NULL
-	NULL
competitor	NULL
Tu	NULL
as	NULL
a	NULL
's	NULL
gn	NULL
a	NULL
``	NULL
/\	NULL
#	NULL
9	NULL
0	NULL
%	NULL
v*5¢/	NULL
#	NULL
~	NULL
Free	NULL
*2p-NF-kB	NULL
1:2	NULL
34-5	NULL
.	NULL

:6..1~	NULL
%	NULL
,8	NULL
.	NULL

9	NULL
.	NULL

.	NULL

;	NULL
10..11	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
(	NULL
1993	NULL
)	NULL
CONTROL	NULL
hrs	NULL
(	NULL
PMA+10	NULL
)	NULL
competitor	NULL
NF-kB	NULL
oligo	NULL
whet	NULL
*2p-ap-1	NULL
7	NULL
.	NULL

6	NULL
C9	NULL
.	NULL

10	NULL
tV	NULL
12°	NULL
13	NULL
PATIENT	NULL
2	NULL
4	NULL
8	NULL
8	NULL
8	NULL
)	NULL
hours	NULL
(	NULL
PMA+lo	NULL
)	NULL
_	NULL
ook	NULL
ok	NULL
o	NULL
%	NULL
_	NULL
competiter	NULL
w	NULL
e	NULL
wie	NULL
Sime	NULL
!	NULL

ig	NULL
.	NULL

Free	NULL
32	NULL
P-NF-IL-1	NULL
2	NULL
3	NULL
,	NULL
405	NULL
6.7	NULL
8	NULL
9	NULL
1011.12	NULL
13	NULL
Mee	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Interaction	NULL
of	NULL
nuclear	NULL
proteins	NULL
from	NULL
patient	NULL
and	NULL
control	NULL
T	NULL
lymphocytes	NULL
with	NULL
functional	NULL
response	NULL
elements	NULL
present	NULL
in	NULL
the	NULL
enhancer	NULL
of	NULL
IL2	NULL
.	NULL

DNA-protein	NULL
complexes	NULL
were	NULL
formed	NULL
between	NULL
*P-end-labeled	NULL
double-stranded	NULL
oligonucleotides	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
patient	NULL
and	NULL
control	NULL
T	NULL
lymphocytes	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
Io	NULL
)	NULL
.	NULL

%	NULL
P-end-labeled	NULL
OCT-lp	NULL
(	NULL
4	NULL
)	NULL
,	NULL
AP-1	NULL
(	NULL
B	NULL
)	NULL
,	NULL
NF-kB	NULL
(	NULL
C	NULL
)	NULL
,	NULL
and	NULL
NF-IL-2B	NULL
(	NULL
D	NULL
)	NULL
oligonucleotides	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
patient	NULL
and	NULL
control	NULL
T	NULL
lymphocytes	NULL
that	NULL
were	NULL
either	NULL
left	NULL
unstimulated	NULL
(	NULL
lanes	NULL
0	NULL
)	NULL
,	NULL
or	NULL
stimulated	NULL
for	NULL
2	NULL
,	NULL
4	NULL
,	NULL
or	NULL
8	NULL
hr	NULL
.	NULL

The	NULL
arrows	NULL
indicate	NULL
the	NULL
specific	NULL
bands	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
unlabeled	NULL
oligonucleotides	NULL
(	NULL
competitor	NULL
)	NULL
and	NULL
not	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
an	NULL
unlabeled	NULL
unrelated	NULL
sequence	NULL
(	NULL
NF-kB	NULL
)	NULL
in	NULL
B	NULL
,	NULL
lane	NULL
13	NULL
,	NULL
or	NULL
by	NULL
a	NULL
mutant	NULL
of	NULL
NF-AT	NULL
sequence	NULL
in	NULL
D	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
13.	NULL
tion	NULL
(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
cytoplasmic	NULL
and	NULL
the	NULL
nuclear	NULL
components	NULL
combine	NULL
in	NULL
the	NULL
nucleus	NULL
,	NULL
and	NULL
the	NULL
resulting	NULL
complex	NULL
binds	NULL
the	NULL
DNA	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
the	NULL
abnormal	NULL
DNA-NF-AT	NULL
complex	NULL
was	NULL
missing	NULL
one	NULL
of	NULL
the	NULL
identified	NULL
components	NULL
,	NULL
we	NULL
used	NULL
preparations	NULL
containing	NULL
the	NULL
cytoplasmic	NULL
or	NULL
the	NULL
nuclear	NULL
component	NULL
isolated	NULL
from	NULL
Jurkat	NULL
cells	NULL
(	NULL
gift	NULL
of	NULL
G.	NULL
R.	NULL
Crabtree	NULL
)	NULL
to	NULL
complement	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
patient	NULL
T	NULL
lymphocytes	NULL
stimulated	NULL
for	NULL
at	NULL
least	NULL
4	NULL
hr	NULL
.	NULL

The	NULL
results	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Neither	NULL
the	NULL
nuclear	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
nor	NULL
the	NULL
cytoplasmic	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
components	NULL
were	NULL
able	NULL
to	NULL
restore	NULL
the	NULL
normal	NULL
electrophoretic	NULL
mobility	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
12	NULL
)	NULL
when	NULL
added	NULL
to	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
activated	NULL
patient	NULL
T	NULL
lymphocytes	NULL
.	NULL

The	NULL
combination	NULL
of	NULL
the	NULL
nuclear	NULL
and	NULL
the	NULL
cytoplasmic	NULL
components	NULL
from	NULL
Jurkat	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
8	NULL
and	NULL
9	NULL
)	NULL
gave	NULL
rise	NULL
to	NULL
a	NULL
binding	NULL
activity	NULL
that	NULL
exhibited	NULL
faster	NULL
electrophoretic	NULL
mobility	NULL
compared	NULL
with	NULL
the	NULL
control	NULL
DNA-NF-AT	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
compare	NULL
lane	NULL
8	NULL
with	NULL
lane	NULL
12	NULL
)	NULL
,	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
observation	NULL
of	NULL
Flanagan	NULL
et	NULL
al	NULL
.	NULL

(	NULL
19	NULL
)	NULL
.	NULL

Interestingly	NULL
this	NULL
migration	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
observed	NULL
with	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
patient	NULL
's	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
compare	NULL
lane	NULL
8	NULL
with	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

To	NULL
analyze	NULL
whether	NULL
the	NULL
abnormal	NULL
NF-AT	NULL
binding	NULL
activity	NULL
was	NULL
associated	NULL
with	NULL
an	NULL
impaired	NULL
enhancer	NULL
function	NULL
,	NULL
we	NULL
transiently	NULL
transfected	NULL
patient	NULL
and	NULL
control	NULL
T	NULL
lymphocytes	NULL
with	NULL
constructs	NULL
in	NULL
which	NULL
either	NULL
the	NULL
regulatory	NULL
region	NULL
of	NULL
IL2	NULL
or	NULL
multimers	NULL
of	NULL
the	NULL
NF-AT	NULL
site	NULL
linked	NULL
to	NULL
the	NULL
y-fibrinogen	NULL
promoter	NULL
were	NULL
inserted	NULL
upstream	NULL
of	NULL
the	NULL
CAT	NULL
reporter	NULL
gene	NULL
.	NULL

Inducible	NULL
CAT	NULL
activity	NULL
was	NULL
then	NULL
determined	NULL
in	NULL
cell	NULL
extracts	NULL
from	NULL
transfected	NULL
T	NULL
lymphocytes	NULL
that	NULL
were	NULL
either	NULL
left	NULL
unstim-	NULL
Immunology	NULL
:	NULL
Castigli	NULL
et	NULL
al	NULL
.	NULL

A	NULL
CONTROL	NULL
PATIENT	NULL
``	NULL
o	NULL
2	NULL
4	NULL
8	NULL
8	NULL
80	NULL
2	NULL
4	NULL
8	NULL
-o-	NULL
-	NULL
-	NULL
+	NULL
#	NULL
1	NULL
+	NULL
0	NULL
8	NULL
|	NULL
hours	NULL
(	NULL
PMA+10	NULL
)	NULL
Mo	NULL
competitor	NULL
+	NULL
mutant	NULL
«	NULL
-+-	NULL
Free	NULL
Frit	NULL
witn	NULL
*p-NF-AT	NULL
1	NULL
,	NULL
2	NULL
>	NULL
8/	NULL
4-5	NULL
67	NULL
8	NULL
.	NULL

9	NULL
10111213	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
(	NULL
1993	NULL
)	NULL
4731	NULL
CONTROL	NULL
PATIENT	NULL
m	NULL
``	NULL
o	NULL
!	NULL

hrs	NULL
(	NULL
PMA+10	NULL
)	NULL
z	NULL
9	NULL
2	NULL
R	NULL
8	NULL
E	NULL
2	NULL
0	NULL
2	NULL
2	NULL
$	NULL
is	NULL
C	NULL
cgfrfpeutoro	NULL
LoL	NULL
L	NULL
oR	NULL
o_	NULL
e	NULL
#	NULL
e	NULL
e	NULL
0	NULL
e	NULL
-	NULL
-	NULL
&	NULL
mutant	NULL
won	NULL
ant	NULL
arm	NULL
w	NULL
aes	NULL
ame	NULL
caree	NULL
aime	NULL
we	NULL
a-+-	NULL
Free	NULL
*p	NULL
-NFAT-IL-4	NULL
1	NULL
(	NULL
2	NULL
$	NULL
06.07	NULL
§	NULL
009.10	NULL
011	NULL
12	NULL
13	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Interaction	NULL
of	NULL
nuclear	NULL
proteins	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
patient	NULL
and	NULL
control	NULL
T	NULL
lymphocytes	NULL
with	NULL
response	NULL
sequences	NULL
present	NULL
in	NULL
the	NULL
enhancer	NULL
of	NULL
IL2	NULL
and	NULL
IL4	NULL
.	NULL

DNA-protein	NULL
complexes	NULL
were	NULL
formed	NULL
between	NULL
*P-labeled	NULL
NF-AT	NULL
(	NULL
4	NULL
)	NULL
or	NULL
NFAT-IL-4	NULL
(	NULL
B	NULL
)	NULL
double-stranded	NULL
oligonucleotides	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
patient	NULL
and	NULL
control	NULL
T	NULL
lymphocytes	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
Io	NULL
)	NULL
.	NULL

The	NULL
same	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
nuclear	NULL
extracts	NULL
obtained	NULL
from	NULL
two	NULL
separated	NULL
preparations	NULL
.	NULL

P-end-labeled	NULL
oligonucleotides	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
patient	NULL
and	NULL
control	NULL
T	NULL
lymphocytes	NULL
which	NULL
were	NULL
either	NULL
left	NULL
unstimulated	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
8	NULL
)	NULL
,	NULL
or	NULL
stimulated	NULL
for	NULL
2	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
9	NULL
)	NULL
,	NULL
4	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
10	NULL
)	NULL
,	NULL
or	NULL
8	NULL
(	NULL
lanes	NULL
5-7	NULL
and	NULL
11-13	NULL
)	NULL
hr	NULL
.	NULL

Arrows	NULL
indicate	NULL
the	NULL
induced	NULL
bands	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
6	NULL
and	NULL
12	NULL
)	NULL
and	NULL
not	NULL
inhibited	NULL
by	NULL
NF-AT	NULL
mutant	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
13	NULL
)	NULL
.	NULL

ulated	NULL
or	NULL
were	NULL
stimulated	NULL
for	NULL
8	NULL
hr	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

Induction	NULL
of	NULL
CAT	NULL
expression	NULL
via	NULL
the	NULL
IL2	NULL
regulatory	NULL
region	NULL
was	NULL
severely	NULL
depressed	NULL
in	NULL
the	NULL
stimulated	NULL
patient	NULL
T	NULL
lymphocytes	NULL
(	NULL
<	NULL
2	NULL
times	NULL
the	NULL
activity	NULL
of	NULL
unstimulated	NULL
cells	NULL
)	NULL
compared	NULL
with	NULL
control	NULL
cells	NULL
(	NULL
up	NULL
to	NULL
a	NULL
I-fold	NULL
increase	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

54	NULL
)	NULL
.	NULL

Most	NULL
important	NULL
,	NULL
induction	NULL
of	NULL
CAT	NULL
expression	NULL
via	NULL
NF-AT	NULL
enhancer	NULL
activity	NULL
was	NULL
significantly	NULL
reduced	NULL
(	NULL
by	NULL
up	NULL
to	NULL
two-thirds	NULL
)	NULL
in	NULL
patient	NULL
T	NULL
lymphocytes	NULL
compared	NULL
with	NULL
controls	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

The	NULL
defective	NULL
NF-AT	NULL
enhancer	NULL
function	NULL
was	NULL
specific	NULL
because	NULL
the	NULL
enhancer	NULL
function	NULL
of	NULL
another	NULL
inducible	NULL
nuclear	NULL
factor	NULL
(	NULL
5	NULL
)	NULL
,	NULL
OCT-1p	NULL
,	NULL
was	NULL
comparable	NULL
in	NULL
patient	NULL
and	NULL
control	NULL
T	NULL
lymphocytes	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
.	NULL

The	NULL
defect	NULL
in	NULL
the	NULL
NF-AT	NULL
enhancer	NULL
function	NULL
was	NULL
also	NULL
reproduced	NULL
when	NULL
patient	NULL
T	NULL
lymphocytes	NULL
were	NULL
compared	NULL
with	NULL
T-cell	NULL
lines	NULL
derived	NULL
from	NULL
different	NULL
donors	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Transfections	NULL
with	NULL
constructs	NULL
in	NULL
which	NULL
multimers	NULL
of	NULL
AP-1	NULL
or	NULL
NF-kB	NULL
sites	NULL
directed	NULL
the	NULL
transcription	NULL
of	NULL
CAT	NULL
gene	NULL
resulted	NULL
in	NULL
similarly	NULL
high	NULL
basal	NULL
CAT	NULL
activity	NULL
in	NULL
both	NULL
patient	NULL
and	NULL
control	NULL
T	NULL
lymphocytes	NULL
,	NULL
which	NULL
was	NULL
not	NULL
further	NULL
induced	NULL
upon	NULL
stimulation	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
might	NULL
reflect	NULL
the	NULL
transfection	NULL
conditions	NULL
;	NULL
culture	NULL
of	NULL
transfected	NULL
T	NULL
lymphocytes	NULL
with	NULL
TCGF	NULL
and	NULL
rIL-2	NULL
during	NULL
the	NULL
40	NULL
hr	NULL
after	NULL
transfection	NULL
could	NULL
have	NULL
induced	NULL
AP-1	NULL
and	NULL
NF-kB	NULL
via	NULL
signal	NULL
transduction	NULL
pathways	NULL
activated	NULL
by	NULL
the	NULL
interaction	NULL
of	NULL
IL-2	NULL
with	NULL
its	NULL
receptor	NULL
or	NULL
of	NULL
other	NULL
growth	NULL
factors	NULL
with	NULL
their	NULL
receptors	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
NF-AT	NULL
and	NULL
OCT	NULL
-1p	NULL
are	NULL
both	NULL
transcription	NULL
factors	NULL
that	NULL
are	NULL
responsive	NULL
only	NULL
to	NULL
signals	NULL
derived	NULL
from	NULL
the	NULL
T-cell	NULL
receptor	NULL
.	NULL

DISCUSSION	NULL
We	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
binding	NULL
and	NULL
the	NULL
enhancer	NULL
activity	NULL
of	NULL
NF-AT	NULL
are	NULL
selectively	NULL
defective	NULL
(	NULL
Figs	NULL
.	NULL

3A	NULL
and	NULL
5B	NULL
)	NULL
in	NULL
a	NULL
patient	NULL
with	NULL
a	NULL
multiple	NULL
lymphokine	NULL
deficiency	NULL
.	NULL

The	NULL
faster	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
DNA-NF-AT	NULL
complex	NULL
indicated	NULL
that	NULL
the	NULL
patient	NULL
T	NULL
lymphocytes	NULL
are	NULL
missing	NULL
a	NULL
component	NULL
of	NULL
the	NULL
NF-AT	NULL
protein	NULL
complex	NULL
.	NULL

Complemen-tation	NULL
experiments	NULL
,	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
patient	NULL
's	NULL
T	NULL
cells	NULL
and	NULL
the	NULL
cytoplasmic	NULL
or	NULL
the	NULL
nuclear	NULL
compo-	NULL
nuclear	NULL
extract	NULL
P	NULL
IP	NULL
P	NULL
_P	NULL
PoP	NULL
-	NULL
-	NULL
-	NULL
-	NULL
C=C	NULL
hours	NULL
(	NULL
PMA+1o	NULL
)	NULL
0	NULL
20	NULL
2	NULL
8	NULL
8	NULL
8	NULL
8	NULL
-	NULL
-	NULL
-	NULL
8	NULL
8	NULL
nuclear	NULL
component	NULL
Kok	NULL
e	NULL
-	NULL
e	NULL
#	NULL
-	NULL
4	NULL
4	NULL
0	NULL
%	NULL
=	NULL
_	NULL
cytoplasmic	NULL
component	NULL
-	NULL
_o	NULL
#	NULL
004	NULL
040	NULL
-o-competitor	NULL
-	NULL
n	NULL
Cee	NULL
C	NULL
Und	NULL
2	NULL
igo	NULL
3	NULL
(	NULL
Cl	NULL
)	NULL
ton	NULL
00	NULL
Cand	NULL
22	NULL
ug	NULL
al	NULL
uy	NULL
'	NULL
!	NULL

-+	NULL
I	NULL
uld	NULL
|	NULL
1/23	NULL
cA	NULL
:	NULL
5:06	NULL
7	NULL
9	NULL
.	NULL

10	NULL
111213	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Reconstitution	NULL
experiments	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
patient	NULL
T	NULL
lymphocytes	NULL
and	NULL
nuclear	NULL
and/or	NULL
cytoplasmic	NULL
components	NULL
from	NULL
Jurkat	NULL
cells	NULL
.	NULL

DNA-protein	NULL
complexes	NULL
were	NULL
formed	NULL
between	NULL
a	NULL
``	NULL
P-labeled	NULL
double-stranded	NULL
NF-AT	NULL
oligonucleotide	NULL
(	NULL
0.1	NULL
ng	NULL
)	NULL
and	NULL
nuclear	NULL
extracts	NULL
(	NULL
2.5	NULL
ug	NULL
or	NULL
5	NULL
ug	NULL
in	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
from	NULL
patient	NULL
T	NULL
lymphocytes	NULL
unstimulated	NULL
(	NULL
lanes	NULL
1-5	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
Io	NULL
)	NULL
for	NULL
2	NULL
hr	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
or	NULL
8	NULL
hr	NULL
(	NULL
lanes	NULL
4-7	NULL
)	NULL
to	NULL
which	NULL
5	NULL
ug	NULL
of	NULL
preparations	NULL
from	NULL
Jurkat	NULL
cells	NULL
containing	NULL
the	NULL
nuclear	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
or	NULL
the	NULL
cytoplasmic	NULL
component	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
were	NULL
added	NULL
.	NULL

Labeled	NULL
NF-AT	NULL
oligonucleotide	NULL
was	NULL
also	NULL
incubated	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
the	NULL
nuclear	NULL
(	NULL
lane	NULL
10	NULL
)	NULL
or	NULL
5	NULL
ug	NULL
of	NULL
the	NULL
cytoplasmic	NULL
(	NULL
lane	NULL
11	NULL
)	NULL
or	NULL
the	NULL
nuclear	NULL
and	NULL
the	NULL
cytoplasmic	NULL
preparations	NULL
from	NULL
Jurkat	NULL
cells	NULL
(	NULL
lanes	NULL
8	NULL
and	NULL
9	NULL
)	NULL
and	NULL
with	NULL
the	NULL
nuclear	NULL
extract	NULL
from	NULL
stimulated	NULL
control	NULL
T	NULL
lymphocytes	NULL
(	NULL
lanes	NULL
12	NULL
and	NULL
13	NULL
)	NULL
.	NULL

Arrows	NULL
indicate	NULL
the	NULL
induced	NULL
bands	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
unlabeled	NULL
NF-AT	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
5	NULL
,	NULL
9	NULL
,	NULL
and	NULL
13	NULL
)	NULL
.	NULL

4732	NULL
Immunology	NULL
:	NULL
Castigh	NULL
et	NULL
al	NULL
.	NULL

A	NULL
40	NULL
w	NULL
E	NULL
Medium	NULL
PMA+ionomycin	NULL
30	NULL
4	NULL
20	NULL
4	NULL
sss	NULL
B	NULL
E	NULL
Medium	NULL
pes	NULL
01201	NULL
PMA+ionomycin	NULL
z	NULL
Eico	NULL
P	NULL
€	NULL
#	NULL
3	NULL
so	NULL
{	NULL
Z	NULL
Z	NULL
so	NULL
|	NULL
P	NULL
is	NULL
é	NULL
8	NULL
10	NULL
!	NULL

Z	NULL
&	NULL
s	NULL
,	NULL
]	NULL
#	NULL
(	NULL
3	NULL
20	NULL
¢	NULL
-	NULL
Control	NULL
NFAT~1	NULL
-	NULL
Control	NULL
NF	NULL
AT~1	NULL
C	NULL
120	NULL
{	NULL
MB	NULL
Medium	NULL
PMA+onomycin	NULL
=-	NULL
Control	NULL
DCT-ip	NULL
Control	NULL
-	NULL
Control	NULL
OCT-1p	NULL
Patient	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Enhancer	NULL
activity	NULL
in	NULL
PMA-	NULL
and	NULL
ionomycin-stimulated	NULL
patient	NULL
and	NULL
control	NULL
T	NULL
lymphocytes	NULL
transiently	NULL
transfected	NULL
with	NULL
expression	NULL
vectors	NULL
containing	NULL
the	NULL
entire	NULL
IL2	NULL
regulatory	NULL
region	NULL
(	NULL
IL2	NULL
bars	NULL
)	NULL
or	NULL
the	NULL
IL-2	NULL
minimal	NULL
promoter	NULL
(	NULL
Control	NULL
bars	NULL
)	NULL
coupled	NULL
upstream	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
A4	NULL
)	NULL
;	NULL
three	NULL
copies	NULL
of	NULL
NF-AT	NULL
site	NULL
from	NULL
the	NULL
IL2	NULL
enhancer	NULL
fused	NULL
to	NULL
the	NULL
y-fibrinogen	NULL
promoter	NULL
(	NULL
NF-AT	NULL
bars	NULL
)	NULL
or	NULL
the	NULL
y-fibrinogen	NULL
promoter	NULL
alone	NULL
(	NULL
Control	NULL
bars	NULL
)	NULL
,	NULL
which	NULL
are	NULL
in	NULL
turn	NULL
ligated	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
B	NULL
)	NULL
;	NULL
or	NULL
four	NULL
copies	NULL
of	NULL
OCT-1p	NULL
site	NULL
from	NULL
the	NULL
IL2	NULL
enhancer	NULL
driving	NULL
the	NULL
transcription	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
through	NULL
y-fibrinogen	NULL
promoter	NULL
(	NULL
OCT-lp	NULL
bars	NULL
)	NULL
or	NULL
the	NULL
yfibrinogen	NULL
promoter	NULL
alone	NULL
(	NULL
Control	NULL
bars	NULL
)	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Bars	NULL
labeled	NULL
``	NULL
*-*	NULL
represent	NULL
the	NULL
background	NULL
measured	NULL
with	NULL
untransfected	NULL
cells	NULL
.	NULL

CAT	NULL
activities	NULL
were	NULL
normalized	NULL
for	NULL
protein	NULL
concentration	NULL
and	NULL
transfection	NULL
efficiency	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
cpm/ug	NULL
.	NULL

The	NULL
numbers	NULL
over	NULL
the	NULL
hatched	NULL
bars	NULL
indicate	NULL
the	NULL
fold	NULL
increase	NULL
of	NULL
the	NULL
CAT	NULL
activity	NULL
in	NULL
transfected	NULL
T	NULL
lymphocytes	NULL
(	NULL
ratio	NULL
of	NULL
cpm/ug	NULL
of	NULL
stimulated	NULL
cells	NULL
:	NULL
cpm/ug	NULL
of	NULL
unstimulated	NULL
cells	NULL
)	NULL
.	NULL

In	NULL
A	NULL
and	NULL
C	NULL
,	NULL
one	NULL
representative	NULL
experiment	NULL
of	NULL
two	NULL
and	NULL
in	NULL
B	NULL
,	NULL
one	NULL
representative	NULL
experiment	NULL
of	NULL
six	NULL
performed	NULL
with	NULL
the	NULL
same	NULL
plasmid	NULL
and	NULL
the	NULL
same	NULL
control	NULL
T	NULL
cell	NULL
line	NULL
are	NULL
shown	NULL
.	NULL

nent	NULL
of	NULL
NF-AT	NULL
,	NULL
suggested	NULL
that	NULL
the	NULL
patient	NULL
's	NULL
T	NULL
lymphocytes	NULL
lacked	NULL
a	NULL
component	NULL
of	NULL
the	NULL
NF-AT	NULL
protein	NULL
complex	NULL
that	NULL
was	NULL
not	NULL
present	NULL
either	NULL
in	NULL
the	NULL
nuclear	NULL
or	NULL
cytoplasmic	NULL
components	NULL
of	NULL
NF-AT	NULL
already	NULL
identified	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
(	NULL
19	NULL
)	NULL
.	NULL

At	NULL
present	NULL
we	NULL
can	NULL
only	NULL
speculate	NULL
on	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
patient	NULL
NF-AT	NULL
defect	NULL
.	NULL

The	NULL
defect	NULL
may	NULL
directly	NULL
involve	NULL
a	NULL
component	NULL
of	NULL
NF-AT	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
NF-AT	NULL
defect	NULL
may	NULL
be	NULL
the	NULL
result	NULL
of	NULL
a	NULL
distinct	NULL
abnormality	NULL
in	NULL
the	NULL
activation	NULL
pathways	NULL
regulating	NULL
NF-AT	NULL
assembly	NULL
.	NULL

Because	NULL
of	NULL
its	NULL
faster	NULL
mobility	NULL
,	NULL
the	NULL
patient	NULL
DNA-NF-AT	NULL
complex	NULL
seems	NULL
to	NULL
lack	NULL
an-as-yet	NULL
unidentified	NULL
component	NULL
that	NULL
is	NULL
important	NULL
for	NULL
NF-AT	NULL
function	NULL
as	NULL
a	NULL
transcriptional	NULL
activator	NULL
(	NULL
Figs	NULL
.	NULL

3	NULL
A	NULL
and	NULL
C	NULL
and	NULL
5	NULL
B	NULL
and	NULL
A	NULL
)	NULL
.	NULL

The	NULL
delayed	NULL
appearance	NULL
of	NULL
the	NULL
aberrant	NULL
DNA-NF-AT	NULL
complex	NULL
suggests	NULL
a	NULL
susceptibility	NULL
of	NULL
a	NULL
mutated	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
(	NULL
1993	NULL
)	NULL
component	NULL
of	NULL
NF-AT	NULL
to	NULL
proteolysis	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
missing	NULL
component	NULL
could	NULL
be	NULL
a	NULL
protein	NULL
that	NULL
must	NULL
be	NULL
rapidly	NULL
synthesized	NULL
or	NULL
modified	NULL
upon	NULL
stimulation	NULL
.	NULL

A	NULL
defect	NULL
affecting	NULL
the	NULL
availability	NULL
or	NULL
the	NULL
regulation	NULL
of	NULL
this	NULL
component	NULL
could	NULL
account	NULL
for	NULL
the	NULL
observed	NULL
abnormality	NULL
in	NULL
NF-AT	NULL
.	NULL

This	NULL
defect	NULL
affected	NULL
not	NULL
only	NULL
the	NULL
NF-AT	NULL
interaction	NULL
with	NULL
its	NULL
response	NULL
element	NULL
present	NULL
in	NULL
the	NULL
enhancer	NULL
of	NULL
IL2	NULL
but	NULL
also	NULL
its	NULL
interaction	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
with	NULL
a	NULL
similar	NULL
response	NULL
element	NULL
present	NULL
in	NULL
the	NULL
enhancer	NULL
of	NULL
IL4	NULL
,	NULL
the	NULL
transcription	NULL
of	NULL
which	NULL
is	NULL
defective	NULL
in	NULL
the	NULL
patient	NULL
T	NULL
lymphocytes	NULL
.	NULL

These	NULL
findings	NULL
raise	NULL
the	NULL
possibility	NULL
that	NULL
NF-AT	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
transcription	NULL
of	NULL
IL3	NULL
and	NULL
ILS5	NULL
,	NULL
which	NULL
are	NULL
also	NULL
defective	NULL
in	NULL
the	NULL
patient	NULL
T	NULL
lymphocytes	NULL
.	NULL

While	NULL
the	NULL
role	NULL
of	NULL
NF-AT	NULL
in	NULL
the	NULL
regulation	NULL
IL2	NULL
is	NULL
well	NULL
established	NULL
,	NULL
its	NULL
role	NULL
in	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
other	NULL
lymphokine	NULL
genes	NULL
remains	NULL
to	NULL
be	NULL
identified	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
defect	NULL
in	NULL
NF-AT	NULL
activity	NULL
could	NULL
account	NULL
for	NULL
the	NULL
multiple	NULL
lymphokine	NULL
deficiency	NULL
in	NULL
this	NULL
child	NULL
.	NULL

This	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
NF-AT-like	NULL
response	NULL
element	NULL
in	NULL
at	NULL
least	NULL
one	NULL
other	NULL
T	NULL
cell-restricted	NULL
lymphokine	NULL
gene	NULL
that	NULL
is	NULL
defective	NULL
in	NULL
the	NULL
patient-namely	NULL
,	NULL
ZL4	NULL
.	NULL

It	NULL
is	NULL
also	NULL
possible	NULL
that	NULL
the	NULL
defective	NULL
component	NULL
of	NULL
NF-AT	NULL
could	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
activity	NULL
of	NULL
distinct	NULL
trans-acting	NULL
factors	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
other	NULL
lymphokines	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Further	NULL
studies	NULL
on	NULL
the	NULL
nature	NULL
of	NULL
NF-AT	NULL
and	NULL
on	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
T	NULL
lymphocyte-specific	NULL
lymphokine	NULL
genes	NULL
are	NULL
needed	NULL
to	NULL
elucidate	NULL
the	NULL
precise	NULL
nature	NULL
of	NULL
the	NULL
gene	NULL
responsible	NULL
for	NULL
the	NULL
multiple	NULL
lymphokine	NULL
defect	NULL
in	NULL
this	NULL
patient	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
Dr.	NULL
G.	NULL
R.	NULL
Crabtree	NULL
and	NULL
his	NULL
coworkers	NULL
for	NULL
the	NULL
reagents	NULL
provided	NULL
and	NULL
discussion	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
AI21163	NULL
,	NULL
A1I28046	NULL
,	NULL
and	NULL
RRO02172	NULL
(	NULL
to	NULL
R.S.G	NULL
.	NULL
)	NULL

;	NULL
AbO5628	NULL
(	NULL
to	NULL
R.A.G	NULL
.	NULL
)	NULL

;	NULL
and	NULL
AI30550	NULL
(	NULL
to	NULL
T.A.C	NULL
.	NULL
)	NULL

.	NULL

Additional	NULL
support	NULL
was	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
March	NULL
of	NULL
Dimes	NULL
(	NULL
to	NULL
T.A.C	NULL
.	NULL
)	NULL

and	NULL
by	NULL
grants	NULL
from	NULL
Home	NULL
Nutritional	NULL
Services	NULL
,	NULL
Inc.	NULL
,	NULL
Critical	NULL
Care	NULL
America	NULL
,	NULL
and	NULL
Caremark	NULL
.	NULL

1	NULL
.	NULL

Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8	NULL
,	NULL
421-452	NULL
.	NULL

2	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Shaw	NULL
,	NULL
J.	NULL
,	NULL
Bush	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Replogle	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Belagaje	NULL
,	NULL
R.	NULL
&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
1715-1724	NULL
.	NULL

3	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Bush	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Morgan	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

165	NULL
,	NULL
395-407	NULL
.	NULL

4	NULL
.	NULL

Kamps	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Corcoran	NULL
,	NULL
L.	NULL
,	NULL
LeBowitz	NULL
,	NULL
J.	NULL
H.	NULL
&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10	NULL
,	NULL
5464-5472	NULL
.	NULL

5	NULL
.	NULL

Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Flanagan	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
Edwards	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Science	NULL
254	NULL
,	NULL
558-562	NULL
.	NULL

6	NULL
.	NULL

-	NULL
Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Irving	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
&	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Science	NULL
261	NULL
,	NULL
313-316	NULL
.	NULL

7	NULL
.	NULL

Williams	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Moolten	NULL
,	NULL
D.	NULL
,	NULL
Buriein	NULL
,	NULL
J.	NULL
,	NULL
Romano	NULL
,	NULL
J.	NULL
,	NULL
Bhaerman	NULL
,	NULL
R.	NULL
,	NULL
Godiliot	NULL
,	NULL
A.	NULL
,	NULL
Mellon	NULL
,	NULL
M.	NULL
,	NULL
Rausher	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
III	NULL
,	NULL
&	NULL
Kant	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Science	NULL
254	NULL
,	NULL
1791-1794	NULL
.	NULL

8	NULL
.	NULL

Sicbenlist	NULL
,	NULL
U.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Bressler	NULL
,	NULL
P.	NULL
,	NULL
Holbrook	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Norris	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Kamoun	NULL
,	NULL
K.	NULL
,	NULL
Kant	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1986	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

6	NULL
,	NULL
3042-3049	NULL
.	NULL

9	NULL
.	NULL

Riegel	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Richie	NULL
,	NULL
E.	NULL
R.	NULL
&	NULL
Allison	NULL
,	NULL
J.	NULL
P.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

144	NULL
,	NULL
3611-3618	NULL
.	NULL

10	NULL
.	NULL

Granelli-Piperno	NULL
,	NULL
A.	NULL
,	NULL
Nolan	NULL
,	NULL
P.	NULL
,	NULL
Inaba	NULL
,	NULL
K.	NULL
&	NULL
Steinman	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172	NULL
,	NULL
1869-1872	NULL
.	NULL

11	NULL
.	NULL

Pahwa	NULL
,	NULL
R.	NULL
,	NULL
Chatila	NULL
,	NULL
T.	NULL
,	NULL
Pahwa	NULL
,	NULL
S.	NULL
,	NULL
Paradise	NULL
,	NULL
C.	NULL
,	NULL
Day	NULL
,	NULL
N.	NULL
K.	NULL
,	NULL
Geha	NULL
,	NULL
R.	NULL
,	NULL
Schwartz	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Slade	NULL
,	NULL
H.	NULL
,	NULL
Oyaizu	NULL
,	NULL
N.	NULL
&	NULL
Good	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86	NULL
,	NULL
5069-5073	NULL
.	NULL

12	NULL
.	NULL

Chatila	NULL
,	NULL
T.	NULL
,	NULL
Castigli	NULL
,	NULL
E.	NULL
,	NULL
Pahwa	NULL
,	NULL
R.	NULL
,	NULL
Pahwa	NULL
,	NULL
S.	NULL
,	NULL
Chirmule	NULL
,	NULL
N.	NULL
,	NULL
Oyaizu	NULL
,	NULL
N.	NULL
,	NULL
Good	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

&	NULL
Geha	NULL
,	NULL
R.	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87	NULL
,	NULL
10033-10037	NULL
.	NULL

13	NULL
.	NULL

Ohlsson	NULL
,	NULL
H.	NULL
&	NULL
Edlund	NULL
,	NULL
T.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
45	NULL
,	NULL
35-44	NULL
.	NULL

14	NULL
.	NULL

Arai	NULL
,	NULL
N.	NULL
,	NULL
Nomura	NULL
,	NULL
D.	NULL
,	NULL
Villaret	NULL
,	NULL
D.	NULL
,	NULL
DeWaal	NULL
Malefijt	NULL
,	NULL
R.	NULL
,	NULL
Seiki	NULL
,	NULL
M.	NULL
,	NULL
Yoshida	NULL
,	NULL
M.	NULL
,	NULL
Minoshima	NULL
,	NULL
S.	NULL
,	NULL
Fukuyama	NULL
,	NULL
R.	NULL
,	NULL
Maekawa	NULL
,	NULL
M.	NULL
,	NULL
Kudoh	NULL
,	NULL
J.	NULL
,	NULL
Shimizu	NULL
,	NULL
N.	NULL
,	NULL
Yokota	NULL
,	NULL
K.	NULL
,	NULL
Abe	NULL
,	NULL
E.	NULL
,	NULL
Yokota	NULL
,	NULL
T.	NULL
,	NULL
Takebe	NULL
,	NULL
Y	NULL
.	NULL

&	NULL
Aray	NULL
,	NULL
K.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

142	NULL
,	NULL
274-282	NULL
.	NULL

15	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
Imagawa	NULL
,	NULL
M.	NULL
,	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Stein	NULL
,	NULL
B.	NULL
,	NULL
Imbra	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Rahmsdorf	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Jonat	NULL
,	NULL
C.	NULL
,	NULL
Herrlich	NULL
,	NULL
P.	NULL
&	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
49	NULL
,	NULL
729-739	NULL
.	NULL

16	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
46	NULL
,	NULL
705-716	NULL
.	NULL

17	NULL
.	NULL

Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Higgins	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Lacy	NULL
,	NULL
E.	NULL
&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
246	NULL
,	NULL
1617-1620	NULL
.	NULL

18	NULL
.	NULL

-	NULL
Skalnik	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
Strauss	NULL
,	NULL
E.	NULL
C.	NULL
&	NULL
Orkin	NULL
,	NULL
S.	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
16736-16744	NULL
.	NULL

19	NULL
.	NULL

Flanagan	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
Corthesy	NULL
,	NULL
B.	NULL
,	NULL
Bram	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
352	NULL
,	NULL
803-807	NULL
.	NULL

